Potential prognostic biomarkers of OSBPL family genes in patients with pancreatic ductal adenocarcinoma

Open

Cheng-Wei Chou, Yu-Hsiu Hsieh, Su-Chi Ku, Wan-Jou Shen, Gangga Anuraga, Hoang Dang Khoa Ta, Kuen-Haur Lee, Yu-Cheng Lee, Cheng-Hsien Lin, Chih-Yang Wang, Wei-Jan Wang

2021 Biomedicines Vol. 9 Issue 11 Article Cited by 28 Quartile

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy with poor survival outcomes. In addition, oxysterol-binding protein-like (OSBPL) family members are reported to be involved in lipid binding and transport and play critical roles in tumorigenesis. However, relationships between PDAC and OSBPL family members have not comprehensively been elucidated. In this study, we used the Oncomine and GEPIA 2 databases to analyze OSBPL transcription expressions in PDAC. The Kaplan–Meier plotter and TIMER 2.0 were used to assess the relationships between overall survival (OS) and immune-infiltration with OSBPL family members. Co-expression data from cBioPortal were downloaded to assess the correlated pathways with OSBPL gene family members using DAVID. The expressions of OSBPL3, OSBPL8, OSBPL10, and OSBPL11 were found to be highly upregulated in PDAC. Low expressions of OSBPL3, OSBPL8, and OSBPL10 indicated longer OS. The functions of OSBPL family members were mainly associated with several potential signaling pathways in cancer cells, including ATP binding, integrin binding, receptor binding, and the renin-angiotensin system (RAS) signaling pathway. The transcription levels of OSBPL gene family members were connected with several immune infiltrates. Collectively, OSBPL family members are influential biomarkers for the early diagnosis of PDAC and have prognostic value, with the promise of precise treatment of PDAC in the future. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Affiliations

Division of Hematology/Medical Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 40705, Taiwan; Department of Biological Science and Technology, China Medical University, Taichung, 40676, Taiwan; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan; College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, 11031, Taiwan; School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan; Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, 40402, Taiwan; Department of Statistics, Faculty of Science and Technology, Universitas PGRI Adi Buana, East Java, Surabaya, 60234, Indonesia; Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan; Research Center for Cancer Biology, China Medical University, Taichung, 40676, Taiwan

Research at a Glance

Premium content — register to unlock

Research at a Glance

Register to unlock

Topics & SDG Alignment

Premium content — register to unlock

Topics & SDG Alignment

Register to unlock

Collaboration

Premium content — register to unlock

Collaboration

Register to unlock

Author Profile (Selected)

Premium content — register to unlock

Author Profile (Selected)

Register to unlock

References Overview

Premium content — register to unlock

References Overview

Register to unlock

Journal & Source

Premium content — register to unlock

Journal & Source

Register to unlock

Metadata & Integrity

Premium content — register to unlock

Metadata & Integrity

Register to unlock